Introduction
============

Pemphigus disease is an autoimmune disease that is characterized by secretion of autoantibodies that act against surface glycoproteins of epithelial cells \[[@b1-dp0804a03]\]. The immunological basis for pemphigus disease includes autoantibodies targeted against keratinocyte surface antigens desmoglein1 and desmoglein3 (DSG1, DSG3) \[[@b2-dp0804a03]\]. These proteins are primarily involved in intercellular cell-to-cell adhesion structures. Pemphigus vulgaris (PV) is a common type of pemphigus disease with painful blistering on the skin and mucous membranes \[[@b3-dp0804a03]\]. Overall, the close link between autoimmune diseases and both endogenous (genetic) and exogenous (environmental) factors has been clearly understood. Exogenous factors include thiol drugs, physical trauma such as burn, ultraviolet exposure, X-ray, neoplasm, hormones and pregnancy, nutritional factors, and emotional stress \[[@b4-dp0804a03]--[@b7-dp0804a03]\].

Among exogenous etiologies, the critical role of microbial agents such as viruses in triggering and flaring autoimmune conditions has been recently discovered. In this regard, the causative role of herpesviruses (HSVs) as the most important human pathogens in the pathogenesis of PV has been recently suggested \[[@b8-dp0804a03]\]. Thus, efforts have been made to clarify viral etiologies for PV and in this way the role of HSVs and cytomegalovirus (CMV) is taken into consideration \[[@b9-dp0804a03],[@b10-dp0804a03]\]. The main common features of both pointed viruses include their ability to survive in the host body for a long time as well as activating periodically \[[@b11-dp0804a03]\]. The human HSVs including herpesviruses 1 and 2 (HSV1/2) and CMV infect between 60% and 90% of the adult population worldwide \[[@b12-dp0804a03],[@b13-dp0804a03]\]. After primary infection, the virus establishes lifelong latency, with periodic reactivations that are effectively controlled by a robust immune response in most infected individuals despite the virus-producing proteins that interfere with adaptive and innate immunity. The activation of T cells is the important aspect of adaptive immunity. Tissue-resident memory (Trm) T cells are a subtype of memory lymphocytes that enter nonlymphoid tissues such as skin and become permanently established without recirculating. Local immune control of viruses can be mediated by Trm T cells through direct killing of infected cells and recruiting circulating memory CD8+ to the skin. Also, Trm T cells maintain HSV1 latency by secreting granzyme B, which degrades the early protein ICP4 that is important in viral replication \[[@b14-dp0804a03],[@b15-dp0804a03]\].

Atypical HSV infections have been described in immunosuppressed patients \[[@b16-dp0804a03]\]. Several studies have suggested the activation or exacerbation of pemphigus after HSV or CMV infections \[[@b17-dp0804a03]\]. More recently, Japanese researchers have detected high levels of HSV in the saliva samples of PV patients \[[@b18-dp0804a03]\]. In this regard, several studies have shown the benefits of adding antiviral therapies to an immunosuppressive therapy in recalcitrant disease \[[@b19-dp0804a03],[@b20-dp0804a03]\]. Several studies also failed to detect herpesviruses in pemphigus patient specimens \[[@b21-dp0804a03],[@b22-dp0804a03]\], suggesting that viruses may have only a transient role for exacerbation of pemphigus disease, although yet to be further defined.

The number of patients with PV in Iran appears to be increasing, and little information is available with regard to the role of HSV1/2 and CMV in triggering PV among the Iranian population. The present study aimed to investigate the plausible role of these viruses (HSV1/2 and CMV) in the exacerbation of PV using serological and molecular methods.

Materials and Methods
=====================

Disease Definitions in PV Patients
----------------------------------

PV patients were categorized as follows: relapse (development of more than 3 new lesions/month that do not heal within a week without treatment, or development of established lesions in a patient whose disease was controlled) and complete remission (absence of new or established lesions in a patient whose all-systemic therapy is discontinued for ≥2 months, or while the patient is receiving minimal therapy) \[[@b23-dp0804a03]\]. Scoring of disease was recorded based on the pemphigus disease area index.

Study Population
----------------

Sixty patients with PV (27 male, 33 female; mean age 46.3 ± 12.7 years) were recruited for the purpose of this case-control study. Patients were selected among inpatients and outpatients who were referred to the pemphigus clinic of Razi Hospital (Tehran, Iran). The diagnosis of pemphigus had been confirmed by histology and direct immunofluorescence. Among patient subjects, 30 were in complete remission as in the control group, whereas the rest (n = 30) were in relapse as in the case group. None of the patients had overt labial herpetic lesions at the time of sampling. All study participants gave informed consent to provide samples for the study, which was approved by the Local Research Ethics Committee of Tehran University of Medical Sciences (approval number: IR.TUMS.MEDICINE.REC.1395.1017 and IR.TUMS.MEDICINE.REC.1395.2472).

Sample Preparation
------------------

For viral detection and determination of specific antibodies, we used blood, skin biopsy, and throat swab samples from patients. After patient consent forms were obtained, one skin specimen or mucosal specimens were obtained by punch biopsy (3 mm) and blood samples were taken from all patients. In addition, a sample from the throat was collected by swabbing. All samples were transferred in cold chain conditions to the virology laboratory. As soon as samples were received, preparation and storage were carried out. Sera (for serology) and buffy coat (for virus detection) were isolated from whole blood and stored at −20°C. DNA extraction from buffy coat, skin biopsy, and throat swab were performed using DNA Isolation Kit for Cells and Tissues according to the manufacturers' instructions (Roche, Berlin, Germany). After DNA extraction, it was eluted in 50 μL of buffer and then adjusted to a definitive concentration of 500 ng/μL.

Virus-Specific Antibody Responses
---------------------------------

HSV1/2- and CMV-immunoglobulin G (IgG) antibodies were determined using enzyme-linked immunosorbent assay (ELISA). Quantification of IgG antibodies was determined by standard curve as RU/mL according to the manufacturer (values greater than 22 RU/mL were defined as seropositive).

DSG-Specific IgG
----------------

The levels of autoantibody to DSG1 and DSG3 were measured by ELISA. The cutoff values were 20 U/mL for both.

Determination of Viral Load
---------------------------

The absolute quantification of HSV1/2 and CMV-specific DNA was performed by real-time polymerase chain reaction (PCR) using the RealStar HSV PCR Kit 1.0 and RealStar CMV PCR Kit 1.0, respectively (Altona Diagnostics; Hamburg, Germany). All stages of the amplification of the viruses' specific target sequences for the detection and quantification of the amplified DNA were carried out according to the manufacturer's instructions. Ten microliters of the DNA extracted from samples in distilled water, and the 4 controls were included in each experiment as a template and a negative control and quantification standards, respectively. Moreover, we performed internal control to identify possible PCR's inhibitor and to confirm the reliability of all reagents of the kit used for each sample. Finally, the concentration of the samples was calculated in copies per microliter and copies per milliliter.

Statistical Analysis
--------------------

The results were presented as mean ± standard deviation for quantitative variables and were summarized by absolute frequencies and percentages for categorical variables. Normality of data was analyzed using the Kolmogorov-Smirnoff test. Categorical variables were compared using chi-squared test or Fisher's exact test when more than 20% of cells with an expected count of less than 5 were observed. Quantitative variables were also compared with t test or Mann-Whitney U test. The association between quantitative variables was assessed using the Pearson correlation test. To determine the main correlates of IgG antibodies against viruses, multivariable linear regression analysis was used. For the statistical analysis, the statistical software SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL) was used. P values of 0.05 or less were considered statistically significant. We used GraphPad Prism software (GraphPad Software, La Jolla, CA) for plotting graphs.

Results
=======

In total, 30 patients with the relapse type of PV and 30 patients with the remission type were assessed. The demographic and clinical features of patients are presented in [Table 1](#t1-dp0804a03){ref-type="table"}. Comparison of the baseline characteristics of the 2 groups ([Table 2](#t2-dp0804a03){ref-type="table"}) showed no difference in gender, mean age, subtypes of disease (mucous or mucocutaneous), or disease duration and oral medications. Regarding medical history, hypertension and hyperlipidemia were more prevalent in those with relapse PV than in the remission group, while no difference was revealed in other underlying comorbidities including diabetes mellitus, history of smoking, coronary artery disease, or thyroid abnormalities.

With regard to DSG-specific IgG positivity in the relapse and remission forms of PV, DSG1-specific IgG was positive in 56.7% of patients with the relapse form and in 20.0% of those with the remission form, indicating a significant difference across the 2 groups (P = 0.003), but the rate of positivity for DSG3-specific IgG in the relapse and remission types was 76.7% and 63.3%, respectively, with no significant difference (P = 0.260). The mean HSV-IgG in the relapse and remission groups was 154.47 ± 66.80 and 151.17 ± 62.73, respectively, with no significant difference (P = 0.844). Moreover, the mean CMV-IgG in the subgroups was 130.30 ± 47.88 and 127.93 ± 53.56, respectively, with no meaningful difference (P = 0.857). There was no correlation between prednisolone dose and HSV-IgG (P = 0.373) or CMV-IgG (P = 0.647). As shown in [Table 3](#t3-dp0804a03){ref-type="table"}, HSV and CMV positivity in PV patients was independent of the source of the samples.

As indicated in [Table 4](#t4-dp0804a03){ref-type="table"} and [Figure 1](#f1-dp0804a03){ref-type="fig"} and using the multivariable linear regression model, the level of HSV-IgG was not associated with the baseline characteristics including demographics, underlying comorbidities, disease duration, and form of PV. However, as shown in [Table 5](#t5-dp0804a03){ref-type="table"} and [Figure 2](#f2-dp0804a03){ref-type="fig"}, the level of CMV-IgG in PV patients was affected by the gender and age factors. The mean CMV-IgG was significantly higher in female than in male patients suffering from PV (142.21 ± 46.60 vs 112.00 ± 50.86, P = 0.020). Also, a direct correlation was revealed between patients' age and the level of CMV-IgG (r coefficient = 0.404, P = 0.001).

Discussion
==========

Several studies have investigated the relationship between viral infections and the initiation or exacerbation of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and diabetes mellitus \[[@b24-dp0804a03]\]. In this regard, efforts have been made to detect viral pathogens in blood samples and skin specimens of patients with pemphigus by techniques such as immunochemistry and PCR for DNA particles. The association between onset or reactivation of pemphigus disease and viral infections may be causal, or as a result of drug-induced immunosuppression which can increase the likelihood of viral infections, or established on the pathogenic connection between viral infection and immune dysregulation leading to autoimmunity. The mechanism of viral induction of autoimmunity can be explained in several ways, including molecular mimicry (due to cross-reactions between pathogen-derived epitopes and self-derived epitopes); bystander activation (due to activation of preexisting autoreactive T cells as a result of the inflammatory environment); epitope spreading (when antigen-presenting cells recognize self-antigens which were not initially directed by the immune system); polyclonal activation (due to infection of B cells by lymphocytotropic viruses which lead to B cell proliferation and increased antibody production); and viral superantigens (encoded by some viruses, are able to activate polyclonal T cells) \[[@b25-dp0804a03]\]. Molecular mimicry is possibly the most acceptable explanation for the association of viral infections and pemphigus. Further explanation is that viruses upregulate production of interferon and interleukins. High levels of interferon gamma lead to increased expression of HLA2 on keratinocytes, making the pemphigus antigen structural site active. Also, overproduction of IL4 and IL10 causes a shift of TH1 to TH2 response which potentiates antibody response \[[@b26-dp0804a03],[@b27-dp0804a03]\].

The role of viruses in the pathogenesis of pemphigus has been assessed in some previous studies. 'The importance of viral infections as an exacerbating factor of PV is neglected by some clinicians. Concerning this, in our current case-control study, we evaluated the probable role of HSV1/2 and CMV in the exacerbation of PV. In our study, a significantly higher number of PV patients (regardless of disease activity) were positive for HSV- and CMV-IgG antibodies, similar to the studies by Tufano et al and Sagi et al \[[@b28-dp0804a03],[@b29-dp0804a03]\]. This may show a history of HSV and CMV exposure in most patients and may indicate more frequent recrudescence of latent viruses \[[@b30-dp0804a03]\]. A significant increase in IgG antibody levels, discovered by comparing relapse and remission samples, indicates an active infection. According to a general consensus, relatively higher IgG levels are associated with a higher probability of having an active viral infection and relatively lower IgG levels represent a previous viral infection rather than an active viral infection. In this regard, Senger et al showed higher levels of HSV1 antibody in patients in the active phase of disease than in remission patients \[[@b31-dp0804a03]\]. In contrast to our study, there was no significant difference in antibody levels between relapse and remission patients. In the studies of Marzano et al and Rahmati-Roodsari et al, similar to our study, only 1 patient had a positive HSV PCR result for skin samples \[[@b32-dp0804a03],[@b33-dp0804a03]\]. These values are less than the findings of the study by Tufano et al, reporting positive HSV PCR in 5 of 7 skin specimens \[[@b29-dp0804a03]\]. Other PCR results show evidence of HSV1 infection in 10% of all blood samples and CMV infection in 16.6% of all blood samples, 10% of all skin samples, and 10% of all throat samples. On the other hand, several studies failed to detect herpes DNA viruses in pemphigus patient specimens \[[@b26-dp0804a03],[@b27-dp0804a03]\]. Senger et al showed the role of HSV1 in exacerbation of pemphigus by using the ELISA technique \[[@b31-dp0804a03]\]. However, we found no correlation between HSV and CMV PCR results or IgG antibody levels and disease activity (relapse or remission). These findings cannot rule out the role of these viruses in exacerbation of the disease; improvement in some patients, especially those with the mucosal form, after receiving antiviral therapy as well as exacerbation of pemphigus after HSV infection are clinical evidence of the possible role of viruses in disease exacerbation \[[@b22-dp0804a03]\]. Therefore, the role of viruses in exacerbation of pemphigus remains a hypothesis and requires further study.

Our study is unique for several reasons. First, we used both ELISA and PCR techniques to find evidence of viruses, whereas most previous studies used only one technique. Second, the samples were sourced from several sites including skin, throat, and blood. Third, we evaluated virus status in relapse and remission PV patients to determine the role of viruses in the exacerbation of the disease, whereas most previous studies examined the status of viruses in newly diagnosed patients and healthy controls to determine the etiological role of viruses. However, this study had some limitations. We could not evaluate other types of pemphigus disease due to their lower prevalence. Because of high costs of the techniques, we were able to investigate only the role of HSV1/2 and CMV in the exacerbation of disease.

Conclusions
===========

In conclusion, our study could not demonstrate the role of HSV1/2 and CMV as triggering factors for PV exacerbation. Further studies are needed to evaluate the potential role of these viruses in PV exacerbation.
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###### 

Demographic and clinical characteristics of pemphigus vulgaris patients

  ID    Sex   Age (Years)   Type   Duration (Years)   Activation   PDN Dose (mg/d)   Drug History                                                              DSG1       DSG3       PDAI
  ----- ----- ------------- ------ ------------------ ------------ ----------------- ------------------------------------------------------------------------- ---------- ---------- ------
  P1    F     72            MCPV   2                  Relapse      15                Azathioprine                                                              Positive   Positive   94
  P2    F     41            MPV    2.5                Remission    5                 Azathioprine                                                              Negative   Positive   0
  P3    F     47            MCPV   4                  Remission    5                 Mycophenolic acid, Azathioprine                                           Negative   Positive   0
  P4    F     48            MCPV   1.5                Remission    5                 Mycophenolic acid                                                         Negative   Positive   0
  P5    F     31            MCPV   2                  Remission    5                 Azathioprine, rituximab                                                   Positive   Positive   0
  P6    F     28            MCPV   5                  Relapse      10                Mycophenolic acid, Azathioprine                                           Positive   Positive   12
  P7    M     61            MCPV   4                  Remission    5                 Azathioprine, Mycophenolic acid, rituximab, Mtx                           Negative   Positive   0
  P8    M     67            MCPV   10                 Relapse      30                Cyclophosphamide, Mycophenolic acid, rituximab                            Negative   Positive   34
  P9    F     63            MCPV   3.5                Remission    0                 Mycophenolic acid monotherapy                                             Negative   Negative   0
  P10   M     41            MCPV   3                  Remission    0                 Mycophenolic acid                                                         Positive   Negative   0
  P11   M     60            MCPV   2.5                Remission    5                 Azathioprine                                                              Negative   Negative   0
  P12   M     45            MCPV   7                  Remission    5                 Mycophenolic acid, Azathioprine                                           Negative   Negative   0
  P13   M     32            MCPV   10                 Remission    7.5               Azathioprine                                                              Negative   Positive   0
  P14   M     41            MCPV   1.5                Remission    5                 Azathioprine, rituximab                                                   Negative   Negative   0
  P15   M     38            MCPV   4                  Remission    10                Azathioprine, mycophenolic acid, rituximab                                Positive   Negative   0
  P16   M     55            MPV    2                  Remission    7.5               Azathioprine                                                              Negative   Positive   0
  P17   M     65            MCPV   2                  Relapse      5                 Azathioprine                                                              Negative   Positive   14
  P18   F     45            MCPV   2                  Relapse      10                Azathioprine                                                              Positive   Positive   12
  P19   F     58            MCPV   2                  Remission    7.5               Azathioprine                                                              Negative   Positive   0
  P20   M     39            MPV    2                  Remission    1.25              Azathioprine                                                              Negative   Negative   0
  P21   F     45            MPV    2                  Relapse      7.5               Mycophenolic acid                                                         Negative   Positive   5
  P22   M     21            MCPV   1                  Relapse      15                Azathioprine                                                              Positive   Positive   34
  P23   F     65            MCPV   12                 Remission    5                 None                                                                      Negative   Positive   0
  P24   F     45            MCPV   10                 Remission    5                 Azathioprine                                                              Negative   Positive   0
  P25   F     33            MCPV   5                  Relapse      0                 Azathioprine                                                                                    15
  P26   M     44            MPV    19                 Remission    7.5               Mycophenolic acid, Azathioprine                                           Negative   Positive   0
  P27   F     54            MCPV   2.5                Remission    5                 Mycophenolic acid, rituximab                                              Positive   Positive   0
  P28   F     62            MCPV   3                  Remission    2.5               Azathioprine                                                              Negative   Negative   0
  P29   F     55            MCPV   1.5                Remission    2.5               Mycophenolic acid, Mtx                                                    Negative   Negative   0
  P30   M     38            MCPV   1.5                Remission    7.5               Rituximab                                                                 Positive   Positive   0
  P31   F     67            MCPV   11                 Remission    5                 Azathioprine, mycophenolic acid, rituximab, Mtx                           Negative   Positive   0
  P32   F     46            MCPV   0.5                Remission    7.5               Rituximab                                                                 Negative   Negative   0
  P33   F     40            MCPV   12                 Remission    10                Azathioprine                                                              Negative   Positive   0
  P34   M     40            MCPV   3                  Relapse      25                Azathioprine, rituximab                                                   Negative   Positive   5
  P35   M     55            MCPV   6                  Remission    7.5               Azathioprine                                                              Negative   Negative   0
  P36   M     35            MCPV   14                 Remission    7.5               Mycophenolic acid, Azathioprine, Mtx, rituximab, IVIG                     Negative   Positive   0
  P37   M     65            MCPV   5                  Relapse      0                 Mycophenolic acid, Azathioprine                                           Positive   Negative   23
  P38   F     74            MCPV   2                  Relapse      7.5               Azathioprine                                                              Positive   Positive   24
  P39   F     32            MCPV   2                  Relapse      10                Rituximab                                                                 Negative   Positive   14
  P40   F     39            MCPV   8                  Relapse      2.5               Mycophenolic acid, rituximab                                              Positive   Positive   3
  P41   F     36            MCPV   5                  Relapse      5                 Mycophenolic acid, Azathioprine                                           Positive   Positive   34
  P42   F     54            MCPV   2                  Relapse      5                 Mycophenolic acid, Azathioprine, Mtx                                      Positive   Positive   12
  P43   F     54            MCPV   6                  Relapse      25                Rituximab, mycophenolic acid                                              Negative   Positive   11
  P44   M     20            MCPV   1                  Relapse      15                Rituximab                                                                 Negative   Negative   5
  P45   F     42            MPV    1                  Remission    2.5               Rituximab                                                                 Negative   Positive   0
  P46   M     38            MPV    3                  Relapse      15                None                                                                      Negative   Positive   27
  P47   F     46            MCPV   15                 Relapse      20                Mycophenolic acid, Azathioprine, Mtx, rituximab, IVIG, cyclophosphamide   Positive   Positive   0
  P48   M     27            MCPV   1.5                Relapse      30                Mycophenolic acid, Azathioprine                                           Positive   Positive   0
  P49   M     42            MCPV   0.5                Relapse      35                None                                                                      Negative   Negative   17
  P50   F     34            MPV    1                  Relapse      10                Mycophenolic acid, Azathioprine, Mtx, rituximab, IVIG, cyclophosphamide                         10
  P51   F     34            MCPV   1                  Relapse      6.25              Rituximab                                                                 Positive   Negative   38
  P52   F     37            MCPV   2                  Relapse      25                Azathioprine, rituximab                                                   Positive   Positive   19
  P53   M     57            MCPV   3                  Relapse      15                Azathioprine                                                              Positive   Positive   84
  P54   M     54            MCPV   5.5                Relapse      2.5               Azathioprine, mycophenolic acid, rituximab, Mtx                           Positive   Negative   12
  P55   F     54            MCPV   2                  Relapse      12.5              Rituximab                                                                 Negative   Positive   8
  P56   F     48            MCPV   1                  Relapse      10                Azathioprine                                                              Positive   Positive   23
  P57   F     60            MCPV   10                 Remission    10                Azathioprine                                                              Negative   Positive   0
  P58   M     29            MCPV   3                  Relapse      5                 Mycophenolic acid, rituximab                                              Positive   Positive   14
  P59   M     45            MCPV   1                  Relapse      15                Azathioprine                                                              Positive   Positive   21
  P60   F     39            MCPV   1.5                Relapse      35                Mycophenolic acid, Azathioprine                                           Negative   Positive   15

Abbreviations: Mtx, methotrexate; DSG, desmoglein; MCPV, mucocutaneous PV; MPV, mucous PV; PDN dose, oral prednisolone dose at the time of the study; PDAI, pemphigus disease area index

###### 

Comparing baseline characteristics between the patients with relapse and those in remission

                                  Relapse Type (n = 30)   Remission Type (n = 30)   P Value
  ------------------------------- ----------------------- ------------------------- ---------
  Male                            12 (40.0)               14 (46.7)                 0.602
  Mean Age, Years (±SD)           44.90 ± 14.30           47.83 ± 11.04             0.377
  Disease Duration, Years (±SD)   3.42 ± 3.14             5.23 ± 4.75               0.086
  Medical History                                                                   
   History of hypertension        9 (30.0)                2 (6.7)                   0.020
   History of hyperlipidemia      5 (16.7)                0 (0.0)                   0.050
   History of diabetes mellitus   5 (16.7)                2 (6.7)                   0.424
   History of smoking             1 (3.3)                 1 (3.3)                   1.000
   History of coronary disease    2 (6.7)                 1 (3.3)                   0.998
   History of AVN                 2 (6.7)                 0 (0.0)                   0.492
   History of hypothyroidism      2 (6.7)                 0 (0.0)                   0.492
  Form of Disease                                                                   0.706
   Mucous                         3 (10.0)                5 (16.7)                  
   Mucocutaneous                  27 (90.0)               25 (83.3)                 
  Medication                                                                        
   Azathioprine                   19 (63.3)               20 (66.7)                 0.787
   Mycophenolic acid              13 (43.3)               13 (43.3)                 1.000
   Rituximab                      12 (40.0)               10 (33.3)                 0.592
   Methotrexate                   4 (13.3)                4 (13.3)                  1.000
   IVIG                           2 (6.7)                 1 (3.3)                   0.999
   Cyclophosphamide               3 (10.0)                0 (0.0)                   0.237

Unless noted otherwise, values represent number (percent).

###### 

Comparison of HSV and CMV detection based on reverse transcriptase polymerase chain reaction techniques according to the source of samples between the patients with relapse and those in remission

            Relapse Type (n = 30)   Remission Type (n = 30)   P Value
  --------- ----------------------- ------------------------- ---------
  HSV                                                         
   Skin     1 (3.3)                 0 (0.0)                   0.998
   PBMC     1 (3.3)                 2 (6.7)                   0.898
   Throat   0 (0.0)                 0 (0.0)                   1.000
  CMV                                                         
   Skin     3 (10.0)                0 (0.0)                   0.237
   PBMC     5 (16.7)                0 (0.0)                   0.052
   Throat   3 (10.0)                0 (0.0)                   0.237

Values represent number (percent).

Abbreviation: PBMC, peripheral blood mononuclear cell.

###### 

Multivariable linear regression model to assess the main correlates of HSV-IgG antibody in patients with pemphigus vulgaris

                     Unstandardized Coefficients   Standardized Coefficients   t        P Value   
  ------------------ ----------------------------- --------------------------- -------- --------- -------
  Sex                −35.727                       164.984                              −0.217    0.829
  Age                −3.982                        18.674                      −0.031   −0.213    0.832
  Type               0.492                         0.809                       0.098    0.608     0.546
  Duration           −10.558                       26.124                      −0.056   −0.404    0.688
  Form               0.825                         2.345                       0.053    0.352     0.726
  Hypertension       −15.421                       19.720                      −0.121   −0.782    0.438
  Hyperlipidemia     0.185                         34.852                      0.001    0.005     0.996
  Diabetes           58.505                        46.066                      0.254    1.270     0.210
  Coronary Disease   −14.900                       33.394                      −0.075   −0.446    0.657
  Smoking            −2.827                        45.347                      −0.010   −0.062    0.951
  (Constant)         67.297                        54.454                      0.190    1.236     0.222

###### 

Multivariable linear regression model to assess the main correlates of CMV-IgG antibody in patients with pemphigus vulgaris

                   Unstandardized Coefficients   Standardized Coefficients   t        P Value   
  ---------------- ----------------------------- --------------------------- -------- --------- -------
  Sex              −62.825                       114.201                              −0.550    0.585
  Age              28.334                        12.926                      0.281    2.192     0.033
  Type             1.196                         0.560                       0.303    2.135     0.038
  Duration         24.026                        18.083                      0.163    1.329     0.190
  Form             −0.515                        1.623                       −0.042   −0.317    0.752
  Hypertension     −2.244                        13.650                      −0.022   −0.164    0.870
  hyperlipidemia   −14.238                       24.124                      −0.110   −0.590    0.558
  Diabetes         12.675                        31.886                      0.070    0.397     0.693
  Coronary dis.    35.510                        23.115                      0.228    1.536     0.131
  Smoking          −46.372                       31.389                      −0.202   −1.477    0.146
  (Constant)       39.650                        37.693                      0.142    1.052     0.298

[^1]: All authors have contributed significantly to this publication.
